{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:01:28Z","timestamp":1792839688895,"version":"4.5.0"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Incarcerated people are disproportionately burdened with hepatitis C virus (HCV) infection and experience elevated risk of reinfection following treatment. Medication for opioid use disorder (MOUD) has been shown to reduce, but not eliminate, reinfection. Research is lacking on patient-level factors associated with HCV reinfection in incarcerated populations in the United States receiving MOUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a case-control study from secondary data analysis of health records among people incarcerated in California state prisons who initiated HCV treatment, achieved sustained virologic response, and began MOUD before sustained virologic response. Case-patients were reinfected within 1 year; controls remained HCV-negative at 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eligible subjects (50 cases; 108 controls) were predominantly male (96.2%), Hispanic\/Latinx (62.7%) or White (29.1%), and median age 36 (range, 23\u201360) years. HCV reinfection was independently associated with injection drug use (adjusted odds ratio [aOR] = 3.4; 95% confidence interval [CI], 1.3\u20138.5), unsterile tattooing (aOR = 3.4; 95% CI, 1.2\u20139.9), methamphetamine use (aOR = 2.5; 95% CI, 1.0\u20136.1), younger age (aOR = 0.7; 95% CI, .5\u2013.9; units = 5 years), and lower adherence to adequately dosed (\u226516\u2005mg\/day) buprenorphine (aOR = 0.7; 95% CI, .6\u20131.0; units = 0.25, aOR = 0.3; 95% CI, .1\u2013.9; units = 1.0).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Even with complete MOUD adherence, conferring a 70% protective effect for HCV reinfection, patients reported ongoing risk behaviors. Injection drug use, methamphetamine use, and unsterile tattooing also increase the risk of other bloodborne or skin and soft tissue infections and overdose. Improved health outcomes could be achieved with integrating enhanced monitoring of MOUD with expanded harm reduction including syringe services and contingency management for treatment of stimulant use disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciaf192","type":"journal-article","created":{"date-parts":[[2025,4,12]],"date-time":"2025-04-12T17:30:25Z","timestamp":1744479025000},"page":"943-949","source":"Crossref","is-referenced-by-count":2,"title":["A Case-Control Study of Hepatitis C Virus Reinfection in Incarcerated Patients in California Receiving Medication for Opioid Use Disorder"],"prefix":"10.1093","volume":"81","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-5258","authenticated-orcid":false,"given":"Joey","family":"Shemuel","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, University of California , Davis, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6941-8697","authenticated-orcid":false,"given":"Amy T","family":"Krawiec","sequence":"additional","affiliation":[{"name":"Medical Services Division, California Correctional Health Care Services , Elk Grove, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Kalauokalani","sequence":"additional","affiliation":[{"name":"Medical Services Division, California Correctional Health Care Services , Elk Grove, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1977-5055","authenticated-orcid":false,"given":"Kimberley D","family":"Lucas","sequence":"additional","affiliation":[{"name":"Medical Services Division, California Correctional Health Care Services , Elk Grove, California ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"2025122403222405500_ciaf192-B1","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/hep.27978","article-title":"Toward a more accurate estimate of the prevalence of hepatitis C in the United States","volume":"62","author":"Edlin","year":"2015","journal-title":"Hepatology"},{"key":"2025122403222405500_ciaf192-B2","doi-asserted-by":"crossref","first-page":"e186371","DOI":"10.1001\/jamanetworkopen.2018.6371","article-title":"Prevalence of hepatitis C virus infection in US states and the District of Columbia, 2013 to 2016","volume":"1","author":"Rosenberg","year":"2018","journal-title":"JAMA Netw Open"},{"key":"2025122403222405500_ciaf192-B3","author":"US Department of Health and Human Services","year":"2020"},{"key":"2025122403222405500_ciaf192-B4","author":"California Correctional Health Care Services"},{"key":"2025122403222405500_ciaf192-B5","first-page":"e0117","article-title":"The hepatitis C care cascade in California state prisons: screening and treatment scale-up and progress toward elimination, 2016\u20132023","volume":"23","author":"Lucas","year":"2024","journal-title":"Clin Liver Dis (Hoboken)"},{"key":"2025122403222405500_ciaf192-B6","volume-title":"ISUDT second annual outcome report: impacts of the integrated substance use disorder treatment program on morbidity and mortality","author":"Allen","year":"2023"},{"key":"2025122403222405500_ciaf192-B7","author":"California Correctional Health Care Services","year":"2024"},{"key":"2025122403222405500_ciaf192-B8","doi-asserted-by":"crossref","first-page":"E462","DOI":"10.1503\/cmaj.181506","article-title":"Opioid agonist treatment dosage and patient-perceived dosage adequacy, and risk of hepatitis C infection among people who inject drugs","volume":"191","author":"Artenie","year":"2019","journal-title":"CMAJ"},{"key":"2025122403222405500_ciaf192-B9","author":"California Department of Public Health"},{"key":"2025122403222405500_ciaf192-B10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0740-5472(00)00104-5","article-title":"Reduced injection frequency and increased entry and retention in drug treatment associated with needle-exchange participation in Seattle drug injectors","volume":"19","author":"Hagan","year":"2000","journal-title":"J Subst Abuse Treat"},{"key":"2025122403222405500_ciaf192-B11","author":"Nafekh","year":"2009"},{"key":"2025122403222405500_ciaf192-B12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drugpo.2018.03.026","article-title":"Safe and unsafe spaces: non-fatal overdose, arrest, and receptive syringe sharing among people who inject drugs in public and semi-public spaces in Baltimore City","volume":"57","author":"Hunter","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025122403222405500_ciaf192-B13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1080\/10550887.2011.642758","article-title":"Effect of buprenorphine dose on treatment outcome","volume":"31","author":"Fareed","year":"2012","journal-title":"J Addict Dis"},{"key":"2025122403222405500_ciaf192-B14","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.3390\/ijerph19074106","article-title":"Effects of buprenorphine dose and therapeutic engagement on illicit opiate use in opioid use disorder treatment trials","volume":"19","author":"Bergen","year":"2022","journal-title":"Int J Environ Res Public Health"},{"key":"2025122403222405500_ciaf192-B15","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1097\/ADM.0000000000001189","article-title":"Evidence on buprenorphine dose limits: a review","volume":"17","author":"Grande","year":"2023","journal-title":"J Addict Med"},{"key":"2025122403222405500_ciaf192-B16","doi-asserted-by":"crossref","first-page":"108317","DOI":"10.1016\/j.drugalcdep.2020.108317","article-title":"Adherence to buprenorphine: an analysis of prescription drug monitoring program data","volume":"216","author":"Pizzicato","year":"2020","journal-title":"Drug Alcohol Depend"},{"key":"2025122403222405500_ciaf192-B17","doi-asserted-by":"crossref","first-page":"e2334540","DOI":"10.1001\/jamanetworkopen.2023.34540","article-title":"Buprenorphine dose and time to discontinuation among patients with opioid use disorder in the era of fentanyl","volume":"6","author":"Chambers","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025122403222405500_ciaf192-B18","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/add.16600","article-title":"Dose-specific clinical outcomes in patients with opioid use disorder treated with 24\u201332\u2005mg\/day of buprenorphine","volume":"119","author":"D'Agata Mount","year":"2024","journal-title":"Addiction"},{"key":"2025122403222405500_ciaf192-B19","doi-asserted-by":"crossref","first-page":"e237036","DOI":"10.1001\/jamanetworkopen.2023.7036","article-title":"Estimated costs and outcomes associated with use and nonuse of medications for opioid use disorder during incarceration and at release in Massachusetts","volume":"6","author":"Chatterjee","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025122403222405500_ciaf192-B20","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1093\/cid\/ciac246","article-title":"Hepatitis C virus reinfection following direct acting antiviral treatment in the prison setting: the SToP-C study","volume":"75","author":"Carson","year":"2022","journal-title":"Clin Infect Dis"},{"key":"2025122403222405500_ciaf192-B21","first-page":"103","article-title":"Prison-based needle and syringe programmes (PNSP)\u2014still highly controversial after all these years","volume":"23","author":"Stover","year":"2016","journal-title":"Drugs"},{"key":"2025122403222405500_ciaf192-B22","volume-title":"Interventions to address HIV in prisons: needle and syringe programmes","author":"Jurgens","year":"2007"},{"key":"2025122403222405500_ciaf192-B23","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/jrh.12623","article-title":"Syringe services programs in the bluegrass: evidence of population health benefits using Kentucky Medicaid data","volume":"38","author":"Bushling","year":"2022","journal-title":"J Rural Health"},{"key":"2025122403222405500_ciaf192-B24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2017.01.020","article-title":"Association between harm reduction intervention uptake and skin and soft tissue infections among people who inject drugs","volume":"174","author":"Dunleavy","year":"2017","journal-title":"Drug Alcohol Depend"},{"key":"2025122403222405500_ciaf192-B25","volume-title":"Evidence-based strategies for preventing opioid overdose: what's working in the United States","author":"Carroll","year":"2018"},{"key":"2025122403222405500_ciaf192-B26","volume-title":"Impact of naloxone availability and distribution within the California Department of Corrections and Rehabilitation (CDCR)","author":"Homans","year":"2024"},{"key":"2025122403222405500_ciaf192-B27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.drugpo.2018.09.009","article-title":"Use of rapid fentanyl test strips among young adults who use drugs","volume":"61","author":"Krieger","year":"2018","journal-title":"Int J Drug Policy"},{"key":"2025122403222405500_ciaf192-B28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","article-title":"Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the Southeastern United States","volume":"63","author":"Peiper","year":"2019","journal-title":"Int J Drug Policy"},{"key":"2025122403222405500_ciaf192-B29","author":"Smith"},{"key":"2025122403222405500_ciaf192-B30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/pubmed\/fdl090","article-title":"Changes in injecting practices associated with the use of a medically supervised safer injection facility","volume":"29","author":"Stoltz","year":"2007","journal-title":"J Public Health (Oxf)"},{"issue":"Suppl 1","key":"2025122403222405500_ciaf192-B31","first-page":"1","article-title":"The ASAM\/AAAP clinical practice guideline on the management of stimulant use disorder","volume":"18","author":"Clinical Guideline Committee (CGC) Members","year":"2024","journal-title":"J Addict Med"},{"key":"2025122403222405500_ciaf192-B32","author":"California Department of Corrections and Rehabilitation"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaf192\/62928848\/ciaf192.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/943\/62928848\/ciaf192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/81\/5\/943\/62928848\/ciaf192.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T08:22:31Z","timestamp":1766564551000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/81\/5\/943\/8113482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":32,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,4,15]]},"published-print":{"date-parts":[[2025,12,24]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaf192","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,15]]},"published":{"date-parts":[[2025,4,15]]}}}